C4X Discovery shares soar on $11m COPD payment from AstraZeneca

C4X Discovery, the AIM-listed drug discovery company, has received a "milestone payment" of $11m from biopharma giant AstraZeneca as part of the progress of its NRF2 Activator programme, causing shares to jump by nearly a half on Wednesday.

Related Keywords

Sean Conroy ,Clive Dix ,Astrazeneca ,Shore Capital ,Discovery ,Shares ,Soar ,1m ,Copd ,Payment ,From ,Category All ,Category Company News ,Category News And Announcements ,Category Small Caps Round Up ,Category Aim Bulletin ,